Telomir Pharmaceuticals
TELO
42 hedge funds and large institutions have $11.9M invested in Telomir Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
8% more funds holding
Funds holding: 39 → 42 (+3)
0.41% more ownership
Funds ownership: 12% → 12.41% (+0.41%)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
20% less capital invested
Capital invested by funds: $14.9M → $11.9M (-$2.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$628K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$188K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$104K |
| 4 |
Bank of New York Mellon
New York
|
+$83.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$68.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
-$229K |
| 2 |
JP Morgan Chase
New York
|
-$141K |
| 3 |
T
Transce3nd
Kyle,
Texas
|
-$119K |
| 4 |
Goldman Sachs
New York
|
-$79.8K |
| 5 |
VF
Virtu Financial
New York
|
-$62K |
TELO Hedge Fund Activity: Q1 2025 in Review
42 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q1 2025, worth a combined $11.9M — down 20% from $14.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TELO positions and 4 closed out — a net gain of 3 holders — while 13 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $628K. The largest seller was Gotham Asset Management, exiting entirely with an estimated $229K sold.
- 42 institutional investors held Telomir Pharmaceuticals (TELO) as of Q1 2025, up from 39 in Q4 2024.
- Funds reported $11.9M of Telomir Pharmaceuticals stock for Q1 2025, down 20% quarter-over-quarter.
- 7 funds opened new Telomir Pharmaceuticals positions in Q1 2025 and 4 closed out, a net change of +3 holders.
- The largest Telomir Pharmaceuticals buyer in Q1 2025 was BlackRock, an estimated $628K added.
- The largest Telomir Pharmaceuticals seller in Q1 2025 was Gotham Asset Management, an estimated $229K sold.
Based on aggregated 13F filings for Q1 2025.